Tetraphase Pharmaceuticals (TTPH) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Share on StockTwits

Tetraphase Pharmaceuticals (NASDAQ:TTPH) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02), Morningstar.com reports. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. The business had revenue of $1.15 million for the quarter, compared to analysts’ expectations of $2.09 million.

TTPH traded down $0.08 during trading hours on Friday, hitting $2.17. 808,354 shares of the company’s stock were exchanged, compared to its average volume of 678,728. Tetraphase Pharmaceuticals has a 12-month low of $2.01 and a 12-month high of $6.97. The company has a market cap of $118.93 million, a P/E ratio of -0.83 and a beta of 2.67.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Friday, August 3rd. B. Riley upped their target price on shares of Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 28th. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 30th. Finally, HC Wainwright upped their target price on shares of Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $6.16.

A number of institutional investors and hedge funds have recently made changes to their positions in TTPH. Flagship Harbor Advisors LLC purchased a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth approximately $104,000. Cubist Systematic Strategies LLC increased its position in shares of Tetraphase Pharmaceuticals by 232.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 24,837 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Tetraphase Pharmaceuticals in the 2nd quarter valued at approximately $179,000. Royce & Associates LP purchased a new stake in shares of Tetraphase Pharmaceuticals in the 2nd quarter valued at approximately $556,000. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Tetraphase Pharmaceuticals by 9.2% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 275,630 shares of the biopharmaceutical company’s stock valued at $984,000 after purchasing an additional 23,337 shares during the last quarter. 41.02% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://weekherald.com/2018/11/10/tetraphase-pharmaceuticals-ttph-issues-quarterly-earnings-results-misses-expectations-by-0-02-eps.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Article: What does earnings per share mean?

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply